Deutsch English Français

Contact

EP1800677

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP1800677

EP1800677 - PREVENTIVE AND/OR THERAPEUTIC AGENT FOR URINE COLLECTION DISORDER ACCOMPANYING LOWER URINARY TRACT OBSTRUCTION [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 22.01.2016 Database last updated on 29.06.2024
Most recent event Tooltip	22.01.2016	Application deemed to be withdrawn	published on 24.02.2016 [2016/08]
Applicant(s)	For all designated states Kissei Pharmaceutical Co., Ltd. 19-48, Yoshino Matsumoto-shi Nagano 399-8710 / JP
	[2007/26]
Inventor(s)	01 / OMORI, Yasuhiro, Kissei Pharmaceutical Co., Ltd. Tokyo Head Office, 3-1-3, Koishikawa, Bunkyo-ku Tokyo 112-0002 / JP
	02 / ARAI, Nobuhiko, Kissei Pharmaceutical Co., Ltd. Tokyo Head Office, 3-1-3, Koishikawa, Bunkyo-ku Tokyo 112-0002 / JP
	03 / SHIMIZU, Tomoji, Kissei Pharmaceutical Co., Ltd. Tokyo Head Office, 3-1-3, Koishikawa, Bunkyo-ku Tokyo 112-0002 / JP
	04 / OKUBO, Yoshio, Kissei Pharmaceutical Co., Ltd. Tokyo Head Office, 3-1-3, Koishikawa, Bunkyo-ku Tokyo 112-0002 / JP
	[2007/26]
Representative(s)	Boult Wade Tennant LLP Salisbury Square House 8 Salisbury Square London EC4Y 8AP / GB
	[N/P]
Former [2014/02]	Boult Wade Tennant Verulam Gardens 70 Gray's Inn Road London WC1X 8BT / GB
Former [2007/26]	Hayes, Adrian Chetwynd, et al Boult Wade Tennant, Verulam Gardens 70 Gray's Inn Road London WC1X 8BT / GB
Application number, filing date	05790516.8	04.10.2005
	[2007/26]
	WO2005JP18334
Priority number, date	JP20040292731	05.10.2004 Original published format: JP 2004292731
	[2007/26]
Filing language	JA
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2006038611
	Date:	13.04.2006
	Language:	EN
	[2006/15]
	Type:	A1 Application with search report
	No.:	EP1800677
	Date:	27.06.2007
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 13.04.2006 takes the place of the publication of the European patent application.
	[2007/26]
Search report(s)	International search report - published on:	JP	13.04.2006
	(Supplementary) European search report - dispatched on:	EP	29.02.2008
Classification	IPC:	A61K31/4045, C07D209/14, // A61P13/02, A61P13/08	[2008/07]
	CPC:	C07D209/14 (EP,KR,US); A61K31/4045 (EP,KR,US); A61K45/06 (EP,KR,US); A61P13/00 (EP); A61P13/02 (EP); A61P13/08 (EP); (+) A61K2300/00 (KR) (-)
	C-Set:	A61K31/4045, A61K2300/00 (EP,US)
	Former IPC [2007/26]	A61K31/4045, A61P13/02, A61P13/08, C07D209/14
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2007/26]
Extension states	AL	Not yet paid
	BA	Not yet paid
	HR	Not yet paid
	MK	Not yet paid
	YU	Not yet paid
Title	German:	MITTEL ZUR PRÄVENTION UND/ODER BEHANDLUNG VON HARNSAMMELSTÖRUNGEN IM ZUSAMMENHANG MIT OBSTRUKTION DER UNTEREN HARNWEGE	[2007/26]
	English:	PREVENTIVE AND/OR THERAPEUTIC AGENT FOR URINE COLLECTION DISORDER ACCOMPANYING LOWER URINARY TRACT OBSTRUCTION	[2007/26]
	French:	AGENT POUR LE TRAITEMENT PROPHYLACTIQUE OU THÉRAPEUTIQUE DES TROUBLES DE COLLECTE DE L'URINE DANS LA VESSIE CONSÉCUTIFS À L'OBSTRUCTION DU CANAL URINAIRE INFÉRIEUR	[2007/26]
Entry into regional phase	13.04.2007	Translation filed
	13.04.2007	National basic fee paid
	13.04.2007	Search fee paid
	13.04.2007	Designation fee(s) paid
	13.04.2007	Examination fee paid
Examination procedure	13.04.2007	Examination requested [2007/26]
	25.06.2008	Despatch of a communication from the examining division (Time limit: M06)
	19.12.2008	Reply to a communication from the examining division
	06.03.2009	Despatch of a communication from the examining division (Time limit: M04)
	02.06.2009	Reply to a communication from the examining division
	07.12.2009	Despatch of a communication from the examining division (Time limit: M06)
	08.06.2010	Reply to a communication from the examining division
	12.07.2011	Despatch of a communication from the examining division (Time limit: M04)
	14.11.2011	Reply to a communication from the examining division
	19.03.2013	Despatch of a communication from the examining division (Time limit: M04)
	16.07.2013	Reply to a communication from the examining division
	03.12.2013	Despatch of a communication from the examining division (Time limit: M04)
	08.04.2014	Reply to a communication from the examining division
	20.04.2015	Communication of intention to grant the patent
	01.09.2015	Application deemed to be withdrawn, date of legal effect [2016/08]
	05.10.2015	Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2016/08]
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 25.06.2008
Fees paid	Renewal fee
	24.10.2007	Renewal fee patent year 03
	27.10.2008	Renewal fee patent year 04
	26.10.2009	Renewal fee patent year 05
	25.10.2010	Renewal fee patent year 06
	24.10.2011	Renewal fee patent year 07
	24.10.2012	Renewal fee patent year 08
	24.10.2013	Renewal fee patent year 09
	27.10.2014	Renewal fee patent year 10
	Penalty fee
	Additional fee for renewal fee
	31.10.2015	11 M06 Not yet paid
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[XP]WO2005027923 (BIOXELL SPA [IT], et al) [XP] 1-6 * claims 1-5, p. 5 last paragr. *;
		[XP]EP1541554 (KISSEI PHARMACEUTICAL [JP]) [XP] 1,2,5 * claims 1-10 (in particular 10), p. 5 paragr. [0035, 0036] *;
		[XP]WO2005085195 (KISSEI PHARMACEUTICAL [JP], et al) [XP] 1-6 * claims 1-5 *;
		[X] - SORBERA L A ET AL, KMD-3213. Treatment of BPH, [alpha]1-adrenoceptor antagonist, DRUGS OF THE FUTURE 2001 SPAIN, VOL. 26, NR. 6, PAGE(S) 553-560, (2001), ISSN 0377-8282, XP002462489 [X] 1-5 * introduction 1st paragr., table 1, p. 556 paragr. 2 p 560 ref. 17 * DOI: http://dx.doi.org/10.1358/dof.2001.026.06.626807
		[Y] - ISHIGURO M ET AL, Identification of binding sites of prazosin, tamsulosin and KMD-3213 with [alpha]1-adrenergic receptor subtypes by molecular modeling, LIFE SCIENCES 11 OCT 2002 UNITED STATES, VOL. 71, NR. 21, PAGE(S) 2531-2541, (20021011), ISSN 0024-3205, XP002462490 [Y] 1-6 * p. 2533 table 2, p. 2540 last parag. of discussion * DOI: http://dx.doi.org/10.1016/S0024-3205(02)02077-5
		[XP] - YOSHIDA M ET AL., "Silodosin, a new effective alpha1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia: Results of a phase 3 randomized, placebo-controlled, double-blind study", INTEGRY, Prous, (20050526), XP002462492 [XP] 1-6 * the whole document *
		[Y] - DEBRUYNE F M J ET AL, The international terazosin trial: A multicentre study of the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia, EUROPEAN UROLOGY 1996 SWITZERLAND, VOL. 30, NR. 3, PAGE(S) 369-376, (1996), ISSN 0302-2838, XP002462491 [Y] 1-6 * abstract *
	International search	[A]WO9915202 (KISSEI PHARMACEUTICAL [JP], et al);
		[A]JP2000247998 (KISSEI PHARMACEUTICAL);
		[A]JP2001288115 (YAMANOUCHI PHARMA CO LTD);
		[X] - YOKOYAMA OSAMU ET AL, "Shin'yaku Tenbo 2004 Dai III Bu Chiryo ni Okeru Saikin no Shin'yaku no Ichizuke -Shin'yaku no Hiroba- Hainyo Chikunyo Shogai Chiryoyaku.", MEDICINE AND DRUG JOURNAL. (SPECIAL EXTRA ISSUE), (20040131), vol. 40, no. S-1, pages 590 - 594, XP002999869
	Examination	- PUPPO, "DO WE KNOW EVERYTHING ABOUT ALPHA-BLOCKADE IN THE MANAGEMENT OF LOWER URINARY TRACT SYMPTOMS?", EUROPEAN UROLOGY, vol. 39(supp), no. suppl02, pages 38 - 41, XP008046403 DOI: http://dx.doi.org/10.1159/000052557
		- PRICE D, "Potential mechanism of action of superselective alpha1-adrenoceptor antagonists", EUROPEAN UROLOGY, vol. 40, no. suppl.4, pages 5 - 11, XP009112787
		- YOKOYAMA OSAMU ET AL, "Shin'yaku Tenbo 2004 Dai III Bu Chiryo ni Okeru Saikin no Shin'yaku no Ichizuke- Shin'yaku no Hiroba- Hainyo Chikunyo Shogai Chiryoyaku", MEDICAL AND DRUG JOURNAL - IYAKU JANARU, IYAKU JANARUSHA, OSAKA, JP, (20040131), vol. 40, ISSN 0287-4741, pages 590 - 594, XP002999869
		- DE REIJKE T M ET AL, "Comparative efficacy of two alpha1-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement", BJU INTERNATIONAL, (200404), vol. 93, no. 6, ISSN 1464-4096, pages 757 - 762
		- DOGGRELL S A, "After ALLHAT: Doxazosin for the treatment of benign prostatic hyperplasia", EXPERT OPINION ON PHARMACOTHERAPY, ASHLEY, LONDON, UK, (20040101), vol. 5, no. 9, doi:10.1517/14656566.5.9.1957, ISSN 1465-6566, pages 1957 - 1964, XP009149939 DOI: http://dx.doi.org/10.1517/14656566.5.9.1957
		- HORIUCHI K ET AL, "The short-term effects of terazosin in Japanese men with benign prostatic hyperplasia", JOURNAL OF NIPPON MEDICAL SCHOOL 2001 JP LNKD- DOI:10.1272/JNMS.68.181, (2001), vol. 68, no. 2, ISSN 1345-4676, pages 181 - 185
		- LUKACS B ET AL, "Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results", UROLOGY, (1996), vol. 48, no. 5, ISSN 0090-4295, pages 731 - 740
	by applicant	- BAOJUN GU ET AL., The Journal of Urology, AMERICAN UROLOGICAL ASSOCIATION, (2004), vol. 172, pages 758 - 762
		- KEIICHI SHISHIDO ET AL., RINSHO HINYOKI KA (CLINICAL UROLOGY), (2003), vol. 57, no. 4, pages 104 - 108
		- YAMAGISHI ET AL., EUROPEAN JOURNAL OF PHARMACOLOGY, (1996), vol. 315, pages 73 - 79
		- DONNA J. SELLERS ET AL., WORLD J. UROL., (2001), vol. 19, page 308

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 34p